Assem Patel
YOU?
Author Swipe
View article: A Multicenter Randomized Double-Masked Study Comparing Preservative-free Brimonidine Tartrate Ophthalmic Solution 0.025% with LUMIFY® 0.025% for Ocular Redness in Adults
A Multicenter Randomized Double-Masked Study Comparing Preservative-free Brimonidine Tartrate Ophthalmic Solution 0.025% with LUMIFY® 0.025% for Ocular Redness in Adults Open
View article: The impact of Demodex blepharitis on patient symptoms and daily life
The impact of Demodex blepharitis on patient symptoms and daily life Open
SIGNIFICANCE Patients with Demodex blepharitis have a considerable symptomatic burden that negatively impacts their daily activities and well-being. Despite chronic manifestations of and problems associated with blepharitis that resulted i…
View article: Supplementary Tables from Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways
Supplementary Tables from Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways Open
Supplementary Tables 1 and 2
View article: Supplementary Figure 1 from Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways
Supplementary Figure 1 from Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways Open
Alterations in esophageal adenocarcinoma in the TCGA dataset, and mapping of alterations onto the RTK-RAS and Cell Cycle pathways.
View article: Data from Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways
Data from Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways Open
Purpose:To delineate recurrent oncogenic driver alterations and dysregulated pathways in esophageal adenocarcinoma and to assess their prognostic value.Experimental Design:We analyzed a large cohort of patients with lower esophageal and ju…
View article: Data from Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways
Data from Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways Open
Purpose:To delineate recurrent oncogenic driver alterations and dysregulated pathways in esophageal adenocarcinoma and to assess their prognostic value.Experimental Design:We analyzed a large cohort of patients with lower esophageal and ju…
View article: Supplementary Figure 1 from Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways
Supplementary Figure 1 from Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways Open
Alterations in esophageal adenocarcinoma in the TCGA dataset, and mapping of alterations onto the RTK-RAS and Cell Cycle pathways.
View article: Supplementary Tables from Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways
Supplementary Tables from Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways Open
Supplementary Tables 1 and 2
View article: Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways
Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways Open
Purpose: To delineate recurrent oncogenic driver alterations and dysregulated pathways in esophageal adenocarcinoma and to assess their prognostic value. Experimental Design: We analyzed a large cohort of patients with lower esophageal and…
View article: International Surgical Outcomes Study (ISOS) sub-study: post-operative infection (Statistical Analysis Plan)
International Surgical Outcomes Study (ISOS) sub-study: post-operative infection (Statistical Analysis Plan) Open
This study will is a pre-specified secondary analysis of the International's Surgical Outcomes Study (ISOS). The aims of this analysis is to describe the prevalence of post-operative infection in an international sample of surgical patient…
View article: Session 3: Beyond the boundaries of Total Mesorectal Excision – where surgeons fear to tread
Session 3: Beyond the boundaries of Total Mesorectal Excision – where surgeons fear to tread Open
Approximately 10–15% of patients present with an advanced rectal cancer that extends beyond the conventional total mesorectal excision ( TME ) planes. In such cases extending the surgery to ensure resection with clear margins (R0 resection…
View article: Session 3: Intra‐operative radiotherapy – creating new surgical boundaries
Session 3: Intra‐operative radiotherapy – creating new surgical boundaries Open
In patients with advanced and recurrent colorectal cancer, surgical resection with clear margins is the greatest challenge and is limited by known anatomical constraints. Preoperative or intra‐operative assessment of the limits of surgical…
View article: Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice
Investigating the feasibility of tumour molecular profiling in gastrointestinal malignancies in routine clinical practice Open
View article: Normal Tissue Complication Probability (NTCP) Modelling of Severe Acute Mucositis using a Novel Oral Mucosal Surface Organ at Risk
Normal Tissue Complication Probability (NTCP) Modelling of Severe Acute Mucositis using a Novel Oral Mucosal Surface Organ at Risk Open
The simpler oral cavity OAR should be preferred over the mucosal surface OAR for NTCP modelling of severe mucositis. We recommend minimising the volume of mucosa receiving intermediate and high doses, where possible.